Sun Pharmaceutical Industries Limited, one of the world’s leading pharmaceutical giants, announced a definitive agreement to acquire Checkpoint Therapeutics in a transaction valued at approximately ₹2,480 crore. This strategic move highlights Sun Pharma’s ongoing commitment to expanding its global footprint and strengthening its innovative oncology and specialty medicine portfolios.
The acquisition marks a major milestone for the company, integrating Checkpoint’s cutting-edge pipeline into Sun Pharma’s robust commercial infrastructure. By securing these innovative therapeutic candidates, Sun Pharma aims to accelerate the delivery of advanced, affordable cancer care solutions to patients worldwide.Checkpoint’s specialized pipeline perfectly aligns with the strategic focus of the company ,that allows it to accelerate growth in highly innovative global therapeutic segments.
This high-value transaction reflects a broader trend among Indian pharmaceutical leaders transitioning from traditional generic markets to high-value global healthcare innovations. The deal is subject to customary closing conditions and regulatory approvals.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
